Age-specific effects of childhood BMI on multiple sclerosis risk: a Mendelian Randomisation study

Introduction

Multiple Sclerosis (MS) is an immune-mediated demyelinating disease of the Central Nervous System (CNS), with both genetic and environmental risk factors¹. Environmental factors including obesity, low serum vitamin D, EBV infection, smoking, air pollution and solvent exposure have all been associated with increased MS risk, although the mechanisms through which they act remain uncertain¹. Traditional epidemiological study designs used to study environmental risk factors - such as case-control and cohort studies - are liable to unmeasured confounding and reverse causation and may yield associations which are not truly causal².

Mendelian Randomisation (MR) is a type of instrumental variable (IV) analysis that uses genetic variants as proxies to examine whether observed associations between an exposure and an outcome are likely to be causal^2,3. Childhood obesity has been identified as a potential causal MS risk factor in both epidemiological⁴ and MR studies^5,6. A consistent finding is that birth weight is not associated with MS risk, whereas higher BMI during later childhood and adolescence appears to be a risk factor^4,7–9. However, BMI during early life is a dynamic trait; it is unknown if there is a crucial point during development when BMI influences subsequent MS risk. Understanding the precise nature and timing of this association may shed light on the biological pathways leading to the clinical development of MS, and may inform targeted obesity prevention programmes in early life. Defining this critical window of effect is almost impossible using MR to instrument BMI at a single time point., and combining GWAS of BMI at different time points from different cohorts may introduce confounding from population stratification.

Longitudinal MR analysis of the effect of BMI during development is now possible due to the recent publication of longitudinal BMI GWAS data from the Norwegian Mother, Father, and Child Cohort Study (MoBa) cohort¹⁰. We set out to explore the causal effect of BMI changes during early life on MS risk and examine the dynamics of this effect over time.

Methods

Results

Age-epoch analysis

We collapsed BMI during childhood into four windows: birth (birth - 6 weeks inclusive), infancy (3 months - 1.5 years inclusive), early childhood (2 years - 5 years inclusive), and later childhood (7 - 8 years). At all time epochs other than birth, genetically-elevated BMI was associated with an increased liability to MS (tables 1 & 2, figure 1, supplementary figures 1&2): birth (OR 0.81, 95% CI 0.50 - 1.31, N_SNPs=7, p=0.39), infancy (OR 1.18, 95% CI 1.04 - 1.33, N_SNPs=18, p = 0.01), early childhood (OR 1.31, 95% CI 1.03 - 1.66, N_SNPs=4, p=0.03), and later childhood (OR 1.34, 95% CI 1.08 - 1.66, N_SNPs=4, p=0.01).

View this table:

• View inline
• View popup
• Download powerpoint

Table 1:

Single Nucleotide Polymorphisms (SNPs) associated with BMI at various time epochs during early life. ‘Epoch’ refers to the time window in question. For each SNP, the nearest gene, and the beta, standard error (SE) and associated P value are given for the association with standardized BMI (at each time point) and with MS (i.e. the beta is the log odds ratio per effect allele copy). EAF – effect allele frequency. BMI – body mass index. SNP – single nucleotide polymorphism. SE – standard error. MS – multiple sclerosis.

View this table:

• View inline
• View popup
• Download powerpoint

Table 2:

MR estimates from the primary analysis of BMI during each time epoch on MS. For each method, the number of included SNPs is included. The IVW (inverse variance weighted) method was used as the primary analytic method. MR – mendelian randomisation.

• Download figure
• Open in new tab

The MR-Egger intercepts did not suggest that unbalanced horizontal pleiotropy was biasing the IVW estimate at any of these epochs (supplementary table 1). Cochran’s test of heterogeneity suggested heterogeneity in the IVW estimators during the birth epoch, but not during any other time window (supplementary table 1). Using the MR-PRESSO method, we found evidence of global pleiotropy for the birth epoch (p<0.001) but no other epochs (infancy p=0.68, early childhood p=0.84, later childhood p=0.43). For the birth epoch, a single outlier (rs11187129) was found to distort the overall MR estimate (P_Outlier< 0.05), and removal of this outlier led to a point estimate closer to the null (beta_corrected = -0.06, p=0.69).

To determine whether these results could be driven by SNPs acting in the opposite causal direction (i.e. influencing childhood BMI via susceptibility to MS), we excluded any SNPs explaining more variance in the outcome than the exposure (Steiger filtering)¹⁶. No SNPs were filtered out using this approach, and thus the causal estimates were unchanged. Leave-one-out sensitivity analysis, in which SNPs are removed in turn from the genetic instrument to ensure no one SNP is driving the result, did not lead to an appreciable change in the MR estimates, although there was some loss of precision (supplementary table 2).

Next, to determine whether the observed MR effects of childhood BMI during infancy, early and late childhood on MS risk could be driven by the effects of these genetic variants on BMI in adulthood, we excluded all variants with nominal evidence of association with adult BMI from a large GWAS of ∼700,000 adults¹². Exclusion of these SNPs did not produce a substantial change in the MR estimates during any epoch, although due to smaller numbers of variants the precision was diminished (supplementary tables 3 & 4; supplementary figure 3). For the later childhood epoch, only one SNP was retained and so the Wald Ratio method was the only method available to carry out the MR analysis.

Discussion

We provide novel evidence from longitudinal two-sample mendelian randomisation that higher BMI from 3 months onwards, but not at birth, may be a causal risk factor for MS. For the first time, we demonstrate an increase in magnitude of the effect size of raised BMI across the lifecourse from early to late childhood, suggesting that the effect of BMI on MS risk increases during the transition from childhood to adolescence. By removing SNPs associated with adult BMI, we provide evidence that these effects cannot be fully explained by effects of the genetic instruments on later-life BMI. These results provide evidence that BMI may influence MS risk earlier in life than previously thought, and support the view that early interventions to prevent childhood obesity may help to prevent some cases of MS.

The key novelty here is the use of MR with longitudinal GWAS from the same cohort to explore the time-varying effects of an exposure, in our case childhood BMI, on MS risk. We use a variety of methods to quantify and account for pleiotropy, and demonstrate using the MR-PRESSO method that pleiotropy is unlikely to influence the positive results we observe at the 3 months - 1.5 years, 2 years - 5 years, and 7 years - 8 years epochs. We demonstrate the value of this approach for unpicking the role of time-varying factors on disease risk, demonstrating a clear trend from a null effect of birthweight to a clear effect of BMI in late childhood, consistent with previous epidemiological findings in MS^7,9.

An important caveat is that we cannot exclude the possibility that the observed effects of genetic instruments for childhood BMI on MS risk may be accounted for by the effects of those variants on adult or adolescent BMI. We aim to overcome this concern by removing all SNPs from the genetic instruments weakly associated with adult BMI from a large and therefore well-powered GWAS of ∼700,000 individuals which would be expected to detect strong effects. Although this sensitivity analysis diminished our power, it is striking that we still observe a strong effect of BMI from 3 months - 1.5 years on MS risk. This question could potentially be further addressed with multivariable mendelian randomisation, however given the small number of variants for each genetic instrument and the high collinearity of childhood and adult BMI, we have not pursued this line of analysis in this study. As larger GWAS and therefore more genetic instruments become available for childhood BMI at different early life stages, this will be the crucial test. Preliminary analyses we have performed suggest that much of the effect we observe may be mediated by persistence of elevated BMI into later life, however given the instability of these estimates we do not have high confidence in these results. Replication in other longitudinal early-life cohorts, such as the Avon Longitudinal Study of Parents and Children, and discovery of more loci which exert age-specific effects on BMI will help to reinforce or refute our findings.

Our results support and extend previous observations regarding the effects of early life BMI on subsequent MS risk. Observational data supports the concept that BMI during adolescence, particularly late teenage years, is a risk factor for MS^4,7,9,18. Mendelian randomisation studies have strengthened the notion that this may be a causal relationship^5,6. It remains debatable whether childhood BMI is a causal risk factor for MS independently of its persistence into adolescence/adulthood, or whether it purely affects MS risk via its strong correlation with BMI in early adult life. In favour of the latter, a recent study used multivariable MR to regress out the effects of genetic instruments for childhood BMI mediated via adult BMI: controlling for the effect of adult BMI abolished the observed MR effect of childhood BMI on MS risk, suggesting that persistently raised BMI into adulthood, rather than transiently increased BMI during childhood, is the causal risk factor⁶. These results, obtained with larger datasets for early life BMI, suggest that what we observe may be driven by the same phenomenon - pleiotropic SNPs acting on MS risk via their effect on BMI in later life rather than in childhood per se. Although we address this concern to an extent by excluding SNPs associated with adult BMI, we cannot exclude this possibility.

A weakness of our study is the relatively small number of SNPs included in the genetic instruments at each time point. This motivated our approach of collapsing SNPs into time epochs based on shared biology and kinetics of BMI during these time windows, however we recognise that this represents an arbitrary simplification of the data. Although at individual time points our MR instruments are under-powered, our epoch instruments all have good power (F statistics > 10) to detect true effects. The clear null effect of birthweight is confirmed using an external, and better-powered, GWAS¹³.

A further possible concern is that population stratification may influence our results, as the exposure GWAS (Norwegian) and outcome GWAS (European) are drawn from slightly different populations. There are three reasons why this is not a major problem for our results. First, the MOBA GWAS were performed on a post-Quality Control subset of individuals who cluster tightly with reference EUR samples from the CEU population (correspondence with authors). Second, these GWAS results show a strong genetic correlation with the ‘comparative body size at age 10’ trait from UK Biobank. Third, allele frequencies for included SNPs are very similar between this GWAS and reference European datasets, such as UKB.

In summary we have provided evidence from longitudinal mendelian randomisation that the relationship between early life BMI and MS seems to follow a gradient, with no effect at birth and a gradually increasing influence on later-life MS risk. The window during which BMI influences MS risk may stretch earlier than previously thought. Further work is required to determine whether these effects are solely mediated via their effect on BMI during early adulthood. Our findings extend previous MR findings in this field and demonstrate the value of studying time-varying risk factors with MR.

Funding

This work was performed at the Preventive Neurology Unit, which is funded by the Barts Charity. BMJ is supported by an MRC Clinical Research Training Fellowship.

Disclosures